NCT07096609 - Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

GIST

Interventions

DRUG

Lenvatinib Capsules

Lenvatinib will be administered orally once daily at a dose of 12 mg (for patients weighing ≥ 60 kg) or 8 mg (for patients weighing \< 60 kg). Each treatment cycle consists of 4 weeks (i.e., 28 days).

Trial Locations (1)

05505

Asan Medical Center, Seoul